HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David Sebag-Montefiore Selected Research

Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)

6/2022Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review.
1/2016Technological advances in radiotherapy of rectal cancer: opportunities and challenges.
2/2015Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David Sebag-Montefiore Research Topics

Disease

31Rectal Neoplasms (Rectal Cancer)
04/2022 - 01/2003
26Neoplasms (Cancer)
04/2022 - 11/2006
13Anus Neoplasms (Anal Cancer)
06/2022 - 09/2008
9Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2020 - 08/2012
8Margins of Excision
10/2016 - 11/2006
5Adenocarcinoma
02/2019 - 03/2009
4AIDS-Related Complex (ARC)
06/2022 - 01/2016
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2021 - 01/2016
4Carcinoma (Carcinomatosis)
12/2015 - 07/2005
2COVID-19
01/2021 - 10/2020
2Prostatic Neoplasms (Prostate Cancer)
11/2019 - 02/2015
1Leukocytosis (Pleocytosis)
06/2022
1Colorectal Neoplasms (Colorectal Cancer)
01/2021
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2021
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2020
1Disease Progression
01/2020
1Fecal Incontinence
01/2019
1Urinary Incontinence
01/2019
1Cystitis
01/2018
1Neoplasm Metastasis (Metastasis)
01/2018
1Second Primary Neoplasms (Neoplasms, Second)
02/2015

Drug/Important Bio-Agent (IBA)

9Fluorouracil (Carac)FDA LinkGeneric
01/2020 - 09/2008
7Capecitabine (Xeloda)FDA Link
02/2019 - 09/2008
6Mitomycin (Mitomycin-C)FDA LinkGeneric
01/2018 - 09/2008
4Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2018 - 02/2012
3Biomarkers (Surrogate Marker)IBA
06/2022 - 01/2017
3Paclitaxel (Taxol)FDA LinkGeneric
01/2020 - 02/2015
3Cisplatin (Platino)FDA LinkGeneric
01/2020 - 08/2012
3Carboplatin (JM8)FDA LinkGeneric
01/2020 - 02/2015
2Biological ProductsIBA
06/2020 - 01/2017
2MercuryIBA
01/2014 - 10/2011
1Nelfinavir (Viracept)FDA Link
02/2019
1Irinotecan (Camptosar)FDA LinkGeneric
10/2017
1Cetuximab (Erbitux)FDA Link
10/2017

Therapy/Procedure

43Radiotherapy
01/2022 - 01/2003
19Chemoradiotherapy
06/2022 - 11/2006
13Therapeutics
06/2022 - 11/2006
11Neoadjuvant Therapy
04/2022 - 10/2006
6Drug Therapy (Chemotherapy)
12/2021 - 03/2009
3Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
06/2022 - 02/2015
3Induction Chemotherapy
02/2019 - 02/2015
2Combined Modality Therapy
12/2021 - 07/2015
2Operative Surgical Procedures
01/2021 - 11/2006
2Adjuvant Chemotherapy
01/2016 - 02/2015
2Maintenance Chemotherapy
05/2013 - 08/2012
1Conformal Radiotherapy
06/2022
1Patient Positioning
11/2019
1Adjuvant Chemoradiotherapy
01/2017
1Proctectomy
07/2005